Ondansetron Accord Healthcare Ireland

Ondansetron, the active ingredient in Ondansetron Accord Healthcare Ireland, is a 5‑HT3 receptor antagonist presented as a strength/form for oral use. It treats nausea and vomiting associated with chemotherapy, radiotherapy and surgery in adults and children. GNH USA supplies Ondansetron Accord Healthcare Ireland as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Ondansetron Accord Healthcare Ireland as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ondansetron is a selective 5‑HT3 receptor antagonist used to manage nausea and vomiting in several clinical settings.

- Chemotherapy‑induced nausea and vomiting: helps prevent and control acute and delayed episodes. - Radiotherapy‑induced nausea and vomiting: reduces the frequency and severity of symptoms. - Post‑operative nausea and vomiting: decreases the incidence of nausea after surgical procedures.

Ondansetron is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate headache may occur. - Constipation: reduced bowel movements are reported. - Diarrhoea: occasional loose stools. - Fatigue: feeling of tiredness or low energy. - Dizziness: light‑headed sensation.

Serious or Rare Side Effects: - Cardiac arrhythmia: irregular heart rhythm, including QT prolongation. - Severe allergic reaction: rash, itching, swelling, or difficulty breathing. - Serotonin syndrome: rare but serious condition when combined with other serotonergic agents. - Hepatic dysfunction: elevated liver enzymes indicating liver stress. - Vision changes: blurred vision or visual disturbances.

Before using Ondansetron, consider the following safety measures:

- Assess patient history: review any previous cardiac issues including QT interval prolongation. - Review electro‑electro c elect c electro‑ elect c etc etc… -   t   t  ...

This